Stocktoria

Pacira BioSciences, Inc. PCRX

Nasdaq · stock · Pharmaceutical Preparations · website · IPO 2011-02-03 · LEI

Pacira BioSciences, Inc. statistics & valuation

Market cap$992.8M
P / E141.1×
P / S1.4×
P / B1.4×
P / FCF7.3×
Net margin1.0%
Return on equity1.0%
FCF margin18.8%
Net debt$213.6M
Net debt / EBITDA1.9×
Enterprise value USD$1.2B
EV / EBITDA10.9×
Earnings yield EBIT/EV1.6%
Return on capital1.7%
Graham number -68.6%$7.44

Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else from the latest financial reports. The Graham number is Benjamin Graham's rough maximum fair value ($7.44); a green figure means the price is below it.

Profitability & efficiency

Net margin (%)
-13.70% -14.90% -0.10% -2.60% 33.90% 7.80% 2.40% 6.20% -14.20% 1.00% 2016201720182019202020212022202320242025
Gross margin (%)
2016201720182019202020212022202320242025
Operating margin (%)
-11.60% -8.70% 4.70% 2.50% 10.80% 16.60% 9.00% 13.00% -10.50% 2.60% 2016201720182019202020212022202320242025
Return on equity (%)
-17.30% -15.20% -0.10% -3.10% 23.50% 5.70% 2.10% 4.80% -12.80% 1.00% 2016201720182019202020212022202320242025
Shares outstanding
37.5M 40.7M 41.2M 41.9M 43.7M 45.6M 46.5M 52.0M 46.2M 45.0M 2016201720182019202020212022202320242025
Net debt ($)
$72.8M $585.3M $369.1M $308.5M $213.6M 2016201720182019202020212022202320242025
Share buybacks ($)
2016201720182019202020212022202320242025
Return on assets (%)
-9.70% -6.80% -0.10% -1.30% 11.40% 2.00% 0.90% 2.70% -6.40% 0.60% 2016201720182019202020212022202320242025
Free cash flow margin (%)
3.20% -0.50% 10.20% 14.30% 9.10% 14.70% 17.30% 20.70% 25.50% 18.80% 2016201720182019202020212022202320242025
Debt / equity (×)
0.50× 0.89× 0.60× 0.75× 0.54× 2016201720182019202020212022202320242025
EPS ($)
-$1.02 -$1.07 -$0.01 -$0.27 $3.33 $0.92 $0.34 $0.89 -$2.15 $0.16 2016201720182019202020212022202320242025

Margins and returns computed from annual filings. Falling shares outstanding = buybacks; rising = dilution. Net debt = debt − cash (negative = net cash).

P / E vs its own history

Pacira BioSciences, Inc. trades at about 148.1× earnings — above its 10-year norm (10-year range 19.8×–1485.5×, median 115.5×).

19.8× 1485.5×

Shaded band = 10-year range (19.8×–1485.5×); dot = today's 148.1×.

Historical P/E = month-end price near each fiscal year-end ÷ that year's EPS. A read on whether the stock is cheap or dear relative to how it has typically been valued — not a forecast.

Key ratios (by fiscal year)

RatioFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Operating margin2.6%-10.5%13.0%9.0%16.6%10.8%2.5%4.7%-8.7%-11.6%
Net margin1.0%-14.2%6.2%2.4%7.8%33.9%-2.6%-0.1%-14.9%-13.7%
FCF margin18.8%25.5%20.7%17.3%14.7%9.1%14.3%10.2%-0.5%3.2%
Return on assets0.6%-6.4%2.7%0.9%2.0%11.4%-1.3%-0.1%-6.8%-9.7%
Return on equity1.0%-12.8%4.8%2.1%5.7%23.5%-3.1%-0.1%-15.2%-17.3%
Debt / equity0.54×0.75×0.60×0.89×—————0.50×
Current ratio4.542.405.243.371.662.573.797.886.965.42

Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.